Related Experiment Video
Updated: Jun 25, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
New prostaglandin derivative for glaucoma treatment
Elena Perrino1, Caterina Uliva, Cecilia Lanzi
1Istituto di Chimica Farmaceutica e Tossicologica 'Pietro Pratesi', University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.
Bioorganic & Medicinal Chemistry Letters
|February 24, 2009
Summary
A novel hydrogen sulfide-releasing latanoprost derivative (ACS 67) effectively lowered intraocular pressure in vivo. This compound also increased glutathione and cGMP, suggesting potential neuroprotective benefits for glaucoma treatment.
Area of Science:
- Ophthalmology
- Pharmacology
- Neuroscience
Background:
- Glaucoma is a leading cause of irreversible blindness worldwide.
- Current treatments aim to reduce intraocular pressure (IOP) but have limitations.
- Hydrogen sulfide (H2S) is an endogenous gasotransmitter with potential therapeutic roles.
Purpose of the Study:
- To synthesize and evaluate a novel hydrogen sulfide-releasing derivative of latanoprost acid (ACS 67).
- To assess the efficacy of ACS 67 in reducing intraocular pressure (IOP) in vivo.
- To investigate the effects of ACS 67 on glutathione (GSH) and cyclic guanosine monophosphate (cGMP) levels in aqueous humor and evaluate its tolerability.
Main Methods:
- Synthesis of ACS 67, a latanoprost acid derivative designed to release hydrogen sulfide.
- In vivo testing in an appropriate animal model to measure IOP reduction.
- Quantification of glutathione (GSH) and cGMP content in aqueous humor post-treatment.
- Assessment of the compound's tolerability.
Main Results:
- ACS 67 demonstrated significant reduction in intraocular pressure (IOP).
- Treatment with ACS 67 led to a marked increase in aqueous humor glutathione (GSH) and cGMP levels.
- The compound exhibited good tolerability in the in vivo model.
Conclusions:
- ACS 67 is a promising new therapeutic agent for lowering IOP.
- The observed increases in GSH and cGMP suggest potential neuroprotective mechanisms.
- This study represents the first report of a hydrogen sulfide-releasing molecule for treating ocular diseases, offering a novel therapeutic strategy for glaucoma.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...